Comparative study of sufentanil self-controlled analgesic pump and oxycodone hydrochloride controlled-release tablets in the treatment of moderate and severe cancer pain

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042972

Enrollment

Unknown

Registered

2021-02-02

Start date

2019-05-01

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

1:sufentanil

2:Oxycodone Hydrochloride

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Tissue or pathology diagnosed as cancer; (2) Aged >= 18 years old and = 2 months; (5) There is cancer-related pain (NRS score 4-10 points) and has never used opioid analgesics; (6) Have normal cognitive ability to record the relief of cancer pain; (7) No intestinal obstruction, dysphagia and other special circumstances where oral analgesics cannot be taken.

Exclusion criteria

Exclusion criteria: (1) Patients during pregnancy and lactation; (2) Severe liver and kidney dysfunction, multiple organ failure and cachexia, etc.; (3) Patients with mental system disease.

Design outcomes

Primary

Measure	Time frame
Pain relief rate;	—

Secondary

Measure	Time frame
Numeric Rating Scale;Number of breakthrough pain;Quality of life score;	—

Countries

China

Contacts

Public ContactYao Weirong

Department of Oncology, Jiangxi Provincial People's Hospital

13907002901@126.com+86 13907002901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026